Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHRGet Free Report) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Friday, June 14th. The shares were sold at an average price of $287.22, for a total value of $1,033,992.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $37,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Trading Up 3.1 %

NASDAQ UTHR traded up $9.00 during trading on Monday, hitting $297.06. 705,181 shares of the company’s stock traded hands, compared to its average volume of 477,460. The stock has a fifty day moving average of $259.42 and a two-hundred day moving average of $239.10. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $297.70. The firm has a market cap of $13.18 billion, a P/E ratio of 13.99, a PEG ratio of 4.29 and a beta of 0.49. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. During the same quarter in the previous year, the company posted $4.86 EPS. United Therapeutics’s revenue for the quarter was up 33.7% on a year-over-year basis. As a group, sell-side analysts expect that United Therapeutics Co. will post 24.61 EPS for the current year.

Institutional Trading of United Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Rise Advisors LLC bought a new stake in United Therapeutics during the 1st quarter valued at $32,000. GAMMA Investing LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $43,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of United Therapeutics by 63.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares during the period. C M Bidwell & Associates Ltd. purchased a new position in United Therapeutics during the 3rd quarter valued at about $91,000. Finally, Janiczek Wealth Management LLC lifted its holdings in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of a number of research analyst reports. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 12th. HC Wainwright reissued a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research note on Thursday, May 2nd. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, June 12th. Finally, Oppenheimer increased their target price on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $312.22.

Read Our Latest Stock Analysis on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.